These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 8627506

  • 1. IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo.
    Olivier M, Eslami Z, Tanner CE.
    J Parasitol; 1996 Feb; 82(1):78-81. PubMed ID: 8627506
    [Abstract] [Full Text] [Related]

  • 2. rIL-2-stimulated splenocytes reactivate the NO2-producing ability of macrophages infected by Leishmania donovani.
    Eslami Z, Tanner CE.
    Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):465-87. PubMed ID: 10946826
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy with IL-2-stimulated splenocytes reduces in vitro the level of Leishmania donovani infection in peritoneal macrophages.
    Eslami Z, Olivier M, Tanner CE.
    Int J Parasitol; 1995 Aug; 25(8):975-81. PubMed ID: 8550297
    [Abstract] [Full Text] [Related]

  • 4. Synergism of IL-2-stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro.
    Eslami Z, Gaucher D, Tanner CE.
    Clin Immunol Immunopathol; 1996 Oct; 81(1):74-81. PubMed ID: 8808645
    [Abstract] [Full Text] [Related]

  • 5. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 6. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
    Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, von Lichtenberg F, David JR.
    Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
    [Abstract] [Full Text] [Related]

  • 7. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
    Reiner NE.
    J Immunol; 1987 Mar 15; 138(6):1919-25. PubMed ID: 3493291
    [Abstract] [Full Text] [Related]

  • 8. Functional heterogeneity of macrophage precursor cells from spleen of Leishmania donovani-infected and untreated mice.
    Hockertz S, Baccarini M, Lohmann-Matthes ML.
    J Immunol; 1989 Apr 01; 142(7):2489-94. PubMed ID: 2926141
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 01; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 10. Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products.
    Reiner NE, Ng W, McMaster WR.
    J Immunol; 1987 Mar 15; 138(6):1926-32. PubMed ID: 2434567
    [Abstract] [Full Text] [Related]

  • 11. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S, Ravindran R, Ali N.
    Vaccine; 2007 Aug 29; 25(35):6544-56. PubMed ID: 17655984
    [Abstract] [Full Text] [Related]

  • 12. Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.
    Reed SG, Barral-Netto M, Inverso JA.
    J Immunol; 1984 Jun 29; 132(6):3116-9. PubMed ID: 6725947
    [Abstract] [Full Text] [Related]

  • 13. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H, Hockertz S.
    Arzneimittelforschung; 1999 Nov 29; 49(11):954-61. PubMed ID: 10604050
    [Abstract] [Full Text] [Related]

  • 14. Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin.
    Reiner NE, Finke JH.
    J Immunol; 1983 Sep 29; 131(3):1487-91. PubMed ID: 6224858
    [Abstract] [Full Text] [Related]

  • 15. Importance of lymphokines in the control of multiplication and dispersion of Leishmania donovani within liver macrophages of resistant and susceptible mice.
    Olivier M, Proulx C, Tanner CE.
    J Parasitol; 1989 Oct 29; 75(5):720-7. PubMed ID: 2529362
    [Abstract] [Full Text] [Related]

  • 16. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 29; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 17. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R, Majumder N, Bhattacharyya Majumdar S, Bhattacharjee S, Banerjee S, Roy S, Majumdar S.
    Scand J Immunol; 2007 Dec 29; 66(6):671-83. PubMed ID: 18021365
    [Abstract] [Full Text] [Related]

  • 18. Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell.
    Manna PP, Chakrabarti G, Bandyopadhyay S.
    Vaccine; 2010 Jan 08; 28(3):803-10. PubMed ID: 19879234
    [Abstract] [Full Text] [Related]

  • 19. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N, Mukherjee S, Das L, Das PK.
    Eur J Immunol; 2003 Jun 08; 33(6):1508-18. PubMed ID: 12778468
    [Abstract] [Full Text] [Related]

  • 20. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.
    Barbi J, Oghumu S, Rosas LE, Carlson T, Lu B, Gerard C, Lezama-Davila CM, Satoskar AR.
    J Infect Dis; 2007 Jun 01; 195(11):1713-7. PubMed ID: 17471442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.